Annual Report 2023

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2023 85 The United Laboratories International Holdings Limited Annual Report 2023 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (a) Segment revenue and results (Continued) Year ended 31 December 2022 Intermediate Bulk Finished Segments products medicine products total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 REVENUE External sales 1,599,205 5,174,726 4,560,331 11,334,262 – 11,334,262 Inter-segment sales 2,718,504 870,178 – 3,588,682 (3,588,682) – Segment revenue 4,317,709 6,044,904 4,560,331 14,922,944 (3,588,682) 11,334,262 RESULT Segment profit (Note) 918,762 385,722 796,191 2,100,675 Share of results of an associate (189) Unallocated other income 104,125 Unallocated corporate expenses (97,343) Unallocated other gains and losses, net (22,378) Impairment losses reversed under expected credit loss model, net 3,471 Finance costs (81,595) Profit before taxation 2,006,766 Note : Segments profit arrived after the deduction of research and development expenditures amounted to RMB593,598,000 of which included intermediate products of RMB102,103,000, bulk medicine of RMB184,351,000 and finished products of RMB307,144,000 for the year ended 31 December 2022.